Intravitreal steroids compared to anti-vascular endothelial growth factor treatment for diabetic macular edema: a meta-analysis.

[1]  C. Lei,et al.  Comparative Efficacy of Pharmacotherapy for Macular Edema Secondary to Retinal Vein Occlusion: A Network Meta-analysis , 2021, Frontiers in Pharmacology.

[2]  M. Gillies,et al.  Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema , 2021, British Journal of Ophthalmology.

[3]  J. Figueira,et al.  Guidelines for the Management of Center-Involving Diabetic Macular Edema: Treatment Options and Patient Monitorization , 2021, Clinical ophthalmology.

[4]  R. Gallemore,et al.  Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options , 2021, Cells.

[5]  S. Mishra,et al.  Intravitreal Dexamethasone Implant Versus Intravitreal Ranibizumab Injection for Treatment of Non-Proliferative Diabetic Macular Edema: A Prospective, Randomized and Blinded trial. , 2020, Current Drug Delivery.

[6]  A. Loewenstein,et al.  The role of steroids in treating diabetic macular oedema in the era of anti-VEGF , 2019, Eye.

[7]  D. Podkowinski,et al.  Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema , 2019, Acta ophthalmologica.

[8]  Lihteh Wu,et al.  Corticosteroids for Diabetic Macular Edema , 2019, Taiwan journal of ophthalmology.

[9]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[10]  Ashish Sharma,et al.  Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study , 2019, International Ophthalmology.

[11]  A. Koh,et al.  First-line treatment algorithm and guidelines in center-involving diabetic macular edema , 2019, European journal of ophthalmology.

[12]  A. Loewenstein,et al.  The Role of Steroids in the Management of Diabetic Macular Edema , 2019, Ophthalmic Research.

[13]  Y. Takamura,et al.  Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema , 2018, Graefe's Archive for Clinical and Experimental Ophthalmology.

[14]  Y. Takamura,et al.  New Strategies for Treatment of Diabetic Macular Edema , 2018, Journal of Ophthalmology.

[15]  Rishi P. Singh,et al.  The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy , 2018, Drugs in context.

[16]  Bo-jie Hu,et al.  A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema , 2018, BMC Ophthalmology.

[17]  M. Maia,et al.  Multicenter, Randomized Clinical Trial to Assess the Effectiveness of Intravitreal Injections of Bevacizumab, Triamcinolone, or Their Combination in the Treatment of Diabetic Macular Edema. , 2017, Ophthalmic surgery, lasers & imaging retina.

[18]  Rishi P. Singh,et al.  Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel. , 2017, Ophthalmic surgery, lasers & imaging retina.

[19]  Sanket U. Shah,et al.  PROSPECTIVE RANDOMIZED SUBJECT-MASKED STUDY OF INTRAVITREAL BEVACIZUMAB MONOTHERAPY VERSUS DEXAMETHASONE IMPLANT MONOTHERAPY IN THE TREATMENT OF PERSISTENT DIABETIC MACULAR EDEMA , 2016, Retina.

[20]  M. Gillies,et al.  Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study). , 2016, Ophthalmology.

[21]  Shibo Tang,et al.  COMPARISON OF INTRAVITREAL TRIAMCINOLONE ACETONIDE VERSUS INTRAVITREAL BEVACIZUMAB AS THE PRIMARY TREATMENT OF CLINICALLY SIGNIFICANT MACULAR EDEMA , 2015, Retina.

[22]  M. Gillies,et al.  A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. , 2014, Ophthalmology.

[23]  Young Gun Park,et al.  Laser-Based Strategies to Treat Diabetic Macular Edema: History and New Promising Therapies , 2014, Journal of ophthalmology.

[24]  T. Yamashita,et al.  Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema. , 2014, Investigative ophthalmology & visual science.

[25]  P. Romero-Aroca,et al.  Laser Treatment for Diabetic Macular Edema in the 21st Century , 2014, Current diabetes reviews.

[26]  F. Boscia,et al.  Intravitreal Steroids for the Treatment of Retinal Diseases , 2014, TheScientificWorldJournal.

[27]  Qing Zhou,et al.  Intravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis. , 2013, International journal of ophthalmology.

[28]  Jay Chhablani,et al.  Characterization of microaneurysm closure after focal laser photocoagulation in diabetic macular edema. , 2013, American journal of ophthalmology.

[29]  M. Ávila,et al.  Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double‐blind study , 2012, Acta ophthalmologica.

[30]  Hyo Kyoung Lee,et al.  Comparison of Intravitreal Bevacizumab Alone or Combined with Triamcinolone versus Triamcinolone in Diabetic Macular Edema: A Randomized Clinical Trial , 2011, Ophthalmologica.

[31]  A. Ellakwa,et al.  Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema , 2011, Clinical ophthalmology.

[32]  M. Mesbah,et al.  Transforming scales of measurement of visual acuity at the group level , 2010, Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians.

[33]  P. Mitchell,et al.  Natural history of branch retinal vein occlusion: an evidence-based systematic review. , 2010, Ophthalmology.

[34]  I. Scott,et al.  Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study) , 2007, British Journal of Ophthalmology.

[35]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[36]  R. Danesi,et al.  Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. , 2016, Pharmacological research.